William N. Voss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William N. Voss has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Gregory C. Ippolito
Texas Biomedical Research Institute
4 shared publications - George Georgiou
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA
3 shared publications - Jonathan R. McDaniel
Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA
3 shared publications - Andrew P. Horton
Department of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute
2 shared publications - Chia-Wei Chou
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
2 shared publications - George Delidakis
Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA
2 shared publications
Latest Publications
- Open Access
- 28 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine
The World Health Organization (WHO) recently recommended the programmatic use of the R21/Matrix-M vaccine for Plasmodium falciparum malaria prevention in children living in malaria-endemic areas. To determine its effects on humoral immunity, we conducted a proteomic analysis of polyclonal IgG antibodies directed against the NANP tetrapeptide of the circumsporozoite protein (CSP), which comprises the vaccine’s core immunogen. In 10 malaria-naïve adult volunteers, R21/Matrix-M induced polarized IgG anti-NANP repertoires, heavily skewed for IGHV3-30/3-33 genes bearing minimal somatic mutation, which remained static in composition following a controlled human malaria infection challenge. Notably, these vaccine-generated antibodies cross-reacted with another protective CSP epitope, the N-terminal junction region, despite its absence from the R21 construct. NANP-specific IGHV3-30/3-33 mAbs mined from polyclonal IgG repertoires blocked sporozoite invasion in vitro and prevented parasitemia in vivo. Overall, R21/Matrix-M elicits polarized, minimally mutated, polyclonal IgG responses that can target multiple protective CSP epitopes, offering molecular insight into the serological basis for its demonstrated efficacy against P. falciparum malaria.
- 28 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Open AccessRepertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine
The World Health Organization (WHO) recently recommended the programmatic use of the R21/Matrix-M vaccine for Plasmodium falciparum malaria prevention in children living in malaria-endemic areas. To determine its effects on humoral immunity, we conducted a proteomic analysis of polyclonal IgG antibodies directed against the NANP tetrapeptide of the circumsporozoite protein (CSP), which comprises the vaccine’s core immunogen. In 10 malaria-naïve adult volunteers, R21/Matrix-M induced polarized IgG anti-NANP repertoires, heavily skewed for IGHV3-30/3-33 genes bearing minimal somatic mutation, which remained static in composition following a controlled human malaria infection challenge. Notably, these vaccine-generated antibodies cross-reacted with another protective CSP epitope, the N-terminal junction region, despite its absence from the R21 construct. NANP-specific IGHV3-30/3-33 mAbs mined from polyclonal IgG repertoires blocked sporozoite invasion in vitro and prevented parasitemia in vivo. Overall, R21/Matrix-M elicits polarized, minimally mutated, polyclonal IgG responses that can target multiple protective CSP epitopes, offering molecular insight into the serological basis for its demonstrated efficacy against P. falciparum malaria.
- Open Access
- 1 August 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (8) , 101668
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
- 1 August 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (8) , 101668
Open AccessHybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
- Open Access
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5099-5111.e8
Rapid characterization of spike variants via mammalian cell surface display
- 1 December 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5099-5111.e8
Open AccessRapid characterization of spike variants via mammalian cell surface display
- Top Cited PapersOpen Access
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6546) , 1108-1112
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
A public anti-COVID antibody repertoire: Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6546) , 1108-1112
Top Cited PapersOpen AccessPrevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
A public anti-COVID antibody repertoire: Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108
- Open Access
- 24 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (17) , eaay9093
A facile technology for the high-throughput sequencing of the paired VH:VL and TCRβ:TCRα repertoires
We report a simple and low-cost one-step high-throughput technology for sequencing the paired antibody/TCR repertoire.
- 24 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (17) , eaay9093
Open AccessA facile technology for the high-throughput sequencing of the paired VH:VL and TCRβ:TCRα repertoires
We report a simple and low-cost one-step high-throughput technology for sequencing the paired antibody/TCR repertoire.